These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 34681695)

  • 1. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
    Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E.
    Ni Y; Nagashimada M; Zhuge F; Zhan L; Nagata N; Tsutsui A; Nakanuma Y; Kaneko S; Ota T
    Sci Rep; 2015 Nov; 5():17192. PubMed ID: 26603489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction.
    Li S; Li X; Chen F; Liu M; Ning L; Yan Y; Zhang S; Huang S; Tu C
    J Nutr Biochem; 2022 Feb; 100():108888. PubMed ID: 34695558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the combined impact of fatty liver-induced TGF-β1 and LPS-activated macrophages in fibrosis through a novel 3D serial section methodology.
    Ishiyama S; Hayatsu M; Toriumi T; Tsuda H; Watanabe K; Kasai H; Kishigami S; Mochizuki K; Mikami Y
    Sci Rep; 2024 May; 14(1):11404. PubMed ID: 38762616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
    Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.
    Hayashida M; Hashimoto K; Ishikawa T; Miyamoto Y
    Int J Exp Pathol; 2019 Apr; 100(2):72-82. PubMed ID: 30887659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
    Baeck C; Wehr A; Karlmark KR; Heymann F; Vucur M; Gassler N; Huss S; Klussmann S; Eulberg D; Luedde T; Trautwein C; Tacke F
    Gut; 2012 Mar; 61(3):416-26. PubMed ID: 21813474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
    Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
    Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure to cigarette smoke precipitates simple hepatosteatosis to NASH in high-fat diet fed mice by inducing oxidative stress.
    Fouda S; Khan A; Chan SMH; Mahzari A; Zhou X; Qin CX; Vlahos R; Ye JM
    Clin Sci (Lond); 2021 Sep; 135(17):2103-2119. PubMed ID: 34427662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artemisia argyi ethanol extract ameliorates nonalcoholic steatohepatitis-induced liver fibrosis by modulating gut microbiota and hepatic signaling.
    Erdenebileg S; Kim M; Nam Y; Cha KH; Le TT; Jung SH; Nho CW
    J Ethnopharmacol; 2024 Oct; 333():118415. PubMed ID: 38848971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse.
    Takano K; Kaneda M; Aoki Y; Fujita N; Chiba S; Michihara S; Han LK; Takahashi R
    J Nat Med; 2024 Jun; 78(3):514-524. PubMed ID: 38498120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
    BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.